Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.73 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | CASP3 | P42574 | 2/20 | 0.46 |
| ▸ | FABP7 | O15540 | 2/20 | 0.44 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | TLR2 | O60603 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13525077 | 1.00 | KMT2A (0.73) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL178687 | 0.95 | KMT2A (0.81) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL29397906 | 0.95 | KMT2A (0.81) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL29423575 | 0.95 | KMT2A (0.81) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL31652641 | 0.94 | KMT2A (0.75) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL29587296 | 0.91 | KMT2A (0.68) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL18429473 | 0.91 | KMT2A (0.68) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL28324366 | 0.91 | KMT2A (0.68) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL29776590 | 0.91 | KMT2A (0.68) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL12878333 | 0.89 | KMT2A (0.61) | KMT2AEPHX2CASP3TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150057431-A1 | COMPOSITIONS FOR TREATING A DISEASE OR CONDITION ASSOCIATED WITH ABNORMAL ANGIOGENESIS | COVX TECHNOLOGIES IRELAND LTD (IE) | 2015-02-26 | — | — | US | disclosed |
| US-8912148-B2 | Methods of treating a disease or condition associated with abnormal angiogenesis | COVX TECHNOLOGY IRELAND, LTD. (IE) | 2014-12-16 | — | — | US | disclosed |
| US-8889631-B2 | Disruptors of early/recycling endosomes | THE UNIVERSITY OF KANSAS (US) | 2014-11-18 | — | — | US | disclosed |
| US-8288349-B2 | Anti-angiogenic compounds | COVX TECHNOLOGY IRELAND, LTD. (IE) | 2012-10-16 | — | — | US | disclosed |
| WO-2010022051-A2 | DISRUPTORS OF EARLY/RECYCLING ENDOSOMES | UNIVERSITY OF KANSAS (US) | 2010-02-25 | — | — | WO | disclosed |
| US-20100041773-A1 | DISRUPTORS OF EARLY/RECYCLING ENDOSOMES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-02-18 | — | — | US | disclosed |
| US-7521425-B2 | Anti-angiogenic compounds | COVX TECHNOLOGIES IRELAND LIMITED (IE) | 2009-04-21 | — | — | US | disclosed |
| US-20090098130-A1 | GLUCAGON-LIKE PROTEIN-1 RECEPTOR (GLP-1R) AGONIST COMPOUNDS | COVX TECHNOLOGIES IRELAND LIMITED (IE) | 2009-04-16 | — | — | US | disclosed |
| US-20080166364-A1 | Conjugated to antibody; thrombospondin receptor targeting | COVX TECHNOLOGY IRELAND, LTD. (IE) | 2008-07-10 | — | — | US | disclosed |
| US-20080152660-A1 | Anti-Angiogenic Compounds | COVX TECHNOLOGIES IRELAND LIMITED (IE) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080166364-A1 | Conjugated to antibody; thrombospondin receptor targeting | TEK, KDR, FLT4 | KMT2A 3959/4885EPHX2 916/4885CASP3 4005/4885 |
| US-20150057431-A1 | COMPOSITIONS FOR TREATING A DISEASE OR CONDITION ASSOCIATED WITH ABNORMAL ANGIOGENESIS | VEGFA, TIE1, TEK | KMT2A 2729/4885EPHX2 208/4885CASP3 2090/4885 |
| US-20090098130-A1 | GLUCAGON-LIKE PROTEIN-1 RECEPTOR (GLP-1R) AGONIST COMPOUNDS | GLP1R, GIPR, GCGR | KMT2A 3783/4885EPHX2 3442/4885CASP3 2436/4885 |
| US-20100041773-A1 | DISRUPTORS OF EARLY/RECYCLING ENDOSOMES | EEA1, NSF, LAMP2 | KMT2A 3012/4885EPHX2 2099/4885CASP3 4142/4885 |
| US-20080152660-A1 | Anti-Angiogenic Compounds | VEGFA, FLT4, KDR | KMT2A 3488/4885EPHX2 568/4885CASP3 2449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.